



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_183_25

You asked:

Q1. How many patients were treated in March 2025 (or latest available month) by the gastroenterology department with the following biologic drugs?

- **Etrasimod**
- **Filgotinib**
- **Golimumab**
- **Mirikizumab**
- **Ozanimod**
- **Risankizumab**
- **Tofacitinib**
- **Upadacitinib**
- **Ustekinumab (Stelara)**
- **Ustekinumab Biosimilar**
- **Vedolizumab**

Please find below a table populated with the information Medicines Management are able to provide at this current time. The period the data relates to is 1 March 25 to 31 March 25, the latest month available.

Please note - Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Medicine	Number of Patients
Etrasimod	0
Filgotinib	**
Golimumab	0
Mirikizumab	0
Ozanimod	0

Risankizumab	14
Tofacitinib	0
Upadacitinib	15
Ustekinumab (Stelara)	**
Ustekinumab Biosimilar	87
Vedolizumab	144

Q2. How many patients were treated in March 2025 (or latest available month) for Crohn's disease with the following biologic drugs?

- **Golimumab**
- **Risankizumab**
- **Upadacitinib**
- **Ustekinumab (Stelara)**
- **Ustekinumab Biosimilar**
- **Vedolizumab**

We can confirm that the Health Board does not centrally record this information.

Unfortunately, our electronic dispensing system does not record the condition for which the medicine is being prescribed. The detailed information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.